

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI911161

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED	03/20/2025
RECEIVING PARTY DATA	
Company Name:	THERAKOS DEVELOPMENT LIMITED
Street Address:	c/o TMF Group, Ground Floor, Two Dockland Central
Internal Address:	Guild Street North Dock
City:	Dublin 1
State/Country:	IRELAND
Postal Code:	D01 K2C5
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	17176013
Application Number:	15974881
Application Number:	16171089
Application Number:	16171096
CORRESPONDENCE DATA	
Fax Number:	8017995800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8017995800
Email:	lledlacek@hollandhart.com
Correspondent Name:	Loren R. HULSE
Address Line 1:	Holland & Hart LLP
Address Line 2:	222 S. Main Street, Suite 2200
Address Line 4:	Salt Lake City, UTAH 84101
ATTORNEY DOCKET NUMBER:	125264.0002
NAME OF SUBMITTER:	Laura Sedlacek
SIGNATURE:	/Laura Sedlacek/
DATE SIGNED:	03/25/2025
Total Attachments: 2	

source=Confirmatory_Assignment_US17176013_15974881_16171089_16171096_MALLINCKRODT_PHARMACEUTIC
source=Confirmatory_Assignment_US17176013_15974881_16171089_16171096_MALLINCKRODT_PHARMACEUTIC

HH Ref. 125264.0002 (USSN 17/176,013, 15/974,881, 16/171,089, 16/171,096)

CONFIRMATORY ASSIGNMENT

This Confirmatory Assignment Agreement is entered as of 29 November 2024 (“Effective Date”) between **MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED** (“ASSIGNOR”), a company having a place of business at College Business and Technology Park, Cruiserath Road, Blanchardstown D15 TX2V, Ireland, and **THERAKOS DEVELOPMENT LIMITED**, formerly Solaris IPCo Limited (“ASSIGNEE”), a company having a place of business at c/o TMF Group, Ground Floor, Two Dockland Central, Guild Street North Dock, Dublin 1, D01 K2C5, Ireland.

The ASSIGNOR hereby confirms assignment and transfer unto the ASSIGNEE of all of its right, title, and interest in and to the following patents and patent applications, including the right to damages for past or future infringement, misappropriation or violation thereof:

TITLE	COUNTRY	APPLICATION NO	FILING DATE	PATENT NO	ISSUE DATE
PROCESSING BLOOD	UNITED STATES OF AMERICA	17/176,013	15 February 2021		
PROCESSING BLOOD	UNITED STATES OF AMERICA	15/974,881	09 May 2018	10,926,020	23 February 2021
PROCESSING BLOOD	UNITED STATES OF AMERICA	16/171,089	25 October 2018	10,940,259	09 March 2021
PROCESSING BLOOD	UNITED STATES OF AMERICA	16/171,096	25 October 2018	10,953,149	23 March 2021

The ASSIGNOR confirms assignment to the ASSIGNEE of all of its right, title and interest in and to (i) such patents and patent applications, (ii) all other patents and patent applications owned by Assignor that issue from, or otherwise claim priority to, any of the foregoing, and (iii) any foreign counterparts owned by Assignor to any of the foregoing (the “ASSIGNED PATENT RIGHTS”);

The ASSIGNOR authorizes the ASSIGNEE to apply for and receive any and all United States and foreign patents for the ASSIGNED PATENT RIGHTS in its own name;

The ASSIGNOR authorizes and requests the issuing authority to issue any and all United States and foreign patents granted on the ASSIGNED PATENT RIGHTS in the name of the ASSIGNEE;

The undersigned are duly authorized to execute this document on behalf of the ASSIGNOR and the ASSIGNEE.

HH Ref. 125264.0002 (USSN 17/176,013, 15/974,881, 16/171,089, 16/171,096)

ASSIGNOR:

Signed on behalf of **MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED**

By: Lars Taavola
Digitally signed by Lars Taavola
Date: 2025.03.20 18:57:47 -04'00'

Execution Date: March 20, 2025

Name Lars Taavola

Title: Vice President, Chief Intellectual Property Counsel

ASSIGNEE

Signed on behalf of **THERAKOS DEVELOPMENT LIMITED**, formerly Solaris IPCo

By: Michael Rehtiene
Signed by:
A9D4D23175464AB

Execution Date: 3/25/2025

Name Michael Rehtiene

Title: Co-CEO Therakos, LLC